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of breast cancersAvailable online 14 September 2015Breast cancer is the second-most prevalent cancer in the
United States, with 234,190 new cases projected to be
diagnosed in 2015. The initial diagnosis is commonly made
early in its disease course due to the use of routine
screening mammography.1 Combined with advances in
adjuvant chemotherapy, this has led to promising overall
outcomes, including a 5-year survival rate of 89.4% and a
10%e12% rate of locoregional recurrence at 20 years for
stage I/II disease.1e3 By comparison, prognosis remains
poor for patients with metastatic disease at diagnosis or
for those who present after initial cure of disease with
distant recurrence.4 Among cases of distant recurrence,
skeletal recurrence occurs frequently and can be accom-
panied by hypercalcemia, pain, and functional compro-
mise often requiring a protracted course of palliative
therapy.5e7
The mechanisms underlying the predilection for skeletal
metastases seen with breast cancer have heretofore been
poorly understood. Hypotheses include expression of
osteolysis-stimulating factors such as parathyroid hormone-
related protein (PTHrP), interleukin-11 (IL-11), macrophage
colony stimulating factor (M-CSF), and vascular endothelial
growth factor (VEGF) by cancer cells.8 Expression of these
factors leads to osteoclast-mediated bone resorption and
chemotaxis of tumor cells to the osteolytic lesion upon
release of growth factors stored within the bone microen-
vironment, creating a self-perpetuating cycle.8Peer review under responsibility of Chongqing Medical
University.
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2352-3042/Copyright ª 2015, Chongqing Medical University. Production
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/In June 2015, Cox et al published their work establishing
a link between expression of a copper-dependent amine
oxidase, lysyl oxidase (LOX), and induction of pre-
metastatic osteolytic lesions in patients with estrogen
receptor-negative (ER-negative) breast cancer. It has pre-
viously been established that hypoxia in a primary breast
adenocarcinoma is associated with an increased risk for
metastasis secondary to expression of hypoxia-inducible
factors (HIFs).9 In the study by Cox et al, expression of a
previously-established primary hypoxic tumor signature was
found to be correlated to metastasis in samples from a
cohort of lymph-node negative breast cancer patients who
did not receive adjuvant therapy. However, the relation-
ship held true only with samples from ER-negative breast
cancers. The authors investigated this correlation further
by performing mass-spectrometry-based analysis of the
hypoxic secretome of the ER-negative MDA-MB-231 breast
cancer parent cell line and an osteotropic clone line (MDA-
BT). Compared to expression in the parental MDA-MB-231
line, expression of LOX was upregulated more than 1.5-
fold in MDA-BT cells. Expression of LOX, known to be
mediated by HIF-1a, appeared to be induced by hypoxia
more than other osteotropic genes in the hypoxic secre-
tome.10 Retrospective analysis of LOX expression in both
the authors’ patient cohort and a supporting patient cohort
showed it to be correlated with frequency of metastasis in
ER-negative breast cancers.
In vivo studies were performed using 4T1-BALB/c mice, a
syngeneic model of spontaneously-metastasizing ER-nega-
tive breast cancer with high levels of LOX expression. Mice
were injected with 4T1Luc (control), 4T1shLOX cells which
have low LOX expression compared to controls, or 4T1and hosting by Elsevier B.V. This is an open access article under the
4.0/).
Figure 1 Tumor overproduction of LOX in ER-negative breast adenocarcinoma induces formation of pre-metastatic osteolytic
lesions. A) Overproduction of cytokines, including PTHrP, IL-11, RANKL, and newly described LOX, induces formation of osteolytic
lesions which may be seeded by cells from the primary tumor. Skeletal recurrence of disease occurs at a distant time point. B) The
mechanism for formation of pre-metastatic osteolytic lesions by cytokines has previously been described to be RANK-dependent,
where osteoblasts are activated to produce RANKL, which binds RANK on the surface of osteoclasts. Downstream effects include
osteoclastogenesis. Cox et al demonstrate that activation of osteoclasts by LOX occurs, but via a RANK-independent pathway.
Commentary 289scrambled control (4T1scr). Relative to the control, 4T1scr
tumors were associated with increased osteolytic lesions
with time while 4T1shLOX tumors led to comparatively
fewer lesions. The role of tumor-secreted, hypoxia-induced
factors in the development of osteolytic lesions is sup-
ported by the fact that the authors obtained similar results
upon injecting tumor-free mice with tumor-conditioned
media (CM) from 4T1shLOX or 4T1scr cell lines. The role
of LOX in the induction of pre-metastatic osteolytic lesions
has been explored across multiple cancer types and appears
to be independent of tumor presence. This was demon-
strated by increased frequency and size of osteolytic le-
sions in non-tumor-bearing mice injected with CM from
originally LOX-deficient SW480 colorectal cancer cells
transformed to overexpress LOX. By comparison, CM from
SW480 cells overexpressing a catalytically-inactive mutant
did not have a similar effect.
The formation of pre-metastatic osteolytic lesion and
subsequent skeletal metastases is due to disruption of bone
homestasis, which normally consists of a balance between
osteoid deposition and resorption (Fig. 1A).8 The mecha-
nism by which LOX causes or perpetuates this imbalance
was studied further. When added to pre-osteoclast cul-
tures, recombinant LOX (rLOX) stimulated osteoclasto-
genesis more potently than receptor activator of nuclear
factor kappa-B ligand (RANKL). Absence of autocrine pro-
duction of RANKL was confirmed by ELISA, allowing the
effect to be attributed wholly to LOX. Greater nuclear
localization of nuclear factor of activated T-cells 1
(NFATc1), a regulator of osteoclastogenesis, was demon-
strated with rLOX treatment compared to treatment with
RANKL. This localization was disrupted in a dose-dependentmanner when osteoclast cultures were treated with anti-
LOX antibody. LOX was additionally shown to increase ter-
minal differentiation and decrease proliferation of calvarial
mouse osteoblasts. This effect was also reversed by treat-
ment with anti-LOX antibodies. Similar induction of differ-
entiation was observed when human osteoblasts of the
SaOS-2 cell line were treated with 4T1scr CM and when
osteoblast and osteoclast numbers were quantified on tibial
endosteal surfaces from tumor-bearing mice.
In a final set of experiments, the authors established the
pre-metastatic nature of osteolytic lesions induced by LOX.
Mice pre-conditioned with 4T1scr CM and LOX antibody
developed a reduced tumor burden than their counterparts
conditioned with 4T1scr CM without the LOX antibody.
Addition of bisphosphonate therapy to CM pre-conditioning
reduced the number of bony metastases at 5 weeks after
injection with tumor cells. Although the priming of sites
before establishment of metastases has been demonstrated
across multiple cancer types, this study is the first to
characterize the molecular mediators of osteolytic lesion
formation in ER-negative breast cancer. LOX and other
proteins of the lysyl oxidase family, which primarily func-
tion to covalently cross-link collagen and/or elastin in the
extracellular matrix (ECM), have previously been shown to
play a role in initiation and progression of multiple tumor
types. Notably, increased expression in both primary tumor
cells and surrounding stroma has been linked to metastasis
of several cancers, including breast cancer.11 However, this
is the first study to establish the specific mechanisms un-
derlying this association with ER-negative breast cancer. It
is also the first to characterize a RANKL-independent
mechanism for osteoclastogenesis by LOX during the
290 Commentarydevelopment of skeletal metastases (Fig. 1B). These find-
ings suggest a role for development of novel, LOX-specific
inhibitors for prophylaxis against skeletal recurrence of
ER-negative breast cancers. Finally, further work is needed
to resolve why the correlation between LOX expression and
skeletal metastasis of breast cancer is limited to the ER-
negative subtype.
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